CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

2008560 citationsJournal Articlebronze Open Access

Authors

Eric D. Hsi · Cleveland Clinic

Roxanne Steinle · Cleveland Clinic

Balaji Balasa · PDL BioPharma (United States)

Susann Szmania · University of Arkansas for Medical Sciences

Aparna Draksharapu · PDL BioPharma (United States)

Benny P. Shum · PDL BioPharma (United States)

Mahrukh Huseni

Abstract

These results suggest that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with HuLuc63 for the treatment of multiple myeloma.

Topics & Keywords

Multiple Myeloma Research and Treatments Monoclonal and Polyclonal Antibodies Research Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 14, Issue 9, pp. 2775-2784

DOI: 10.1158/1078-0432.ccr-07-4246

Field-Weighted Citation Impact: 5.92